Skip to main content
Search
Search
Search
Search
Main navigation
About pCPA
Who we are
Governance
Strategic plan
Reports
What's new
FAQs
Careers
Negotiations
Recent updates
Forms and publications
Brand name drugs
Negotiations status
Negotiation process
Generic drugs
Biologics/Biosimilars
pCPA Temporary Access Process (pTAP)
Contact us
EN
FR
Ilumya (tildrakizumab)
pCPA File Number:
21496
Negotiation Status:
Concluded with an LOI
Indication(s):
Psoriasis, moderate to severe plaque
Sponsor/Manufacturer:
Sun Pharma Canada Inc.
CDA-AMC Project Number:
SR0624
pCPA Engagement Letter Issued:
2021-09-17
Negotiation Process Concluded:
2021-12-20